Semaglutide: GLP-1 Receptor Evidence, Outcomes and Limitations
Semaglutide is a long-acting GLP-1 receptor agonist with extensive clinical evidence in regulated formulations. Research content must distinguish that evidence from catalogue material.Biological context and mechanismGLP-1 receptor signalling supports glucose-dependent insulin secretion, suppresses glucagon in a glucose-dependent context…